<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p171" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_171{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_171{left:306px;bottom:30px;}
#t3_171{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_171{left:346px;bottom:30px;}
#t5_171{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_171{left:517px;bottom:30px;}
#t7_171{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_171{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_171{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_171{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_171{left:35px;bottom:777px;letter-spacing:0.1px;word-spacing:0.09px;}
#tc_171{left:35px;bottom:754px;letter-spacing:0.09px;word-spacing:0.1px;}
#td_171{left:35px;bottom:731px;letter-spacing:0.08px;word-spacing:0.1px;}
#te_171{left:35px;bottom:707px;letter-spacing:-0.09px;}
#tf_171{left:35px;bottom:667px;letter-spacing:0.14px;word-spacing:-0.08px;}
#tg_171{left:35px;bottom:645px;letter-spacing:0.23px;word-spacing:-0.24px;}
#th_171{left:35px;bottom:622px;}
#ti_171{left:45px;bottom:629px;letter-spacing:0.61px;}
#tj_171{left:60px;bottom:622px;letter-spacing:0.11px;word-spacing:0.08px;}
#tk_171{left:230px;bottom:629px;letter-spacing:-0.01px;}
#tl_171{left:253px;bottom:622px;letter-spacing:0.23px;word-spacing:-0.05px;}
#tm_171{left:479px;bottom:622px;letter-spacing:0.07px;word-spacing:0.12px;}
#tn_171{left:576px;bottom:622px;letter-spacing:0.43px;}
#to_171{left:35px;bottom:583px;letter-spacing:-0.06px;word-spacing:0.49px;}
#tp_171{left:35px;bottom:559px;letter-spacing:0.13px;word-spacing:0.06px;}
#tq_171{left:35px;bottom:536px;letter-spacing:0.15px;word-spacing:0.03px;}
#tr_171{left:527px;bottom:544px;letter-spacing:0.1px;}
#ts_171{left:35px;bottom:513px;letter-spacing:0.13px;word-spacing:0.05px;}
#tt_171{left:35px;bottom:490px;letter-spacing:0.07px;word-spacing:0.12px;}
#tu_171{left:35px;bottom:467px;letter-spacing:0.1px;word-spacing:0.09px;}
#tv_171{left:35px;bottom:443px;letter-spacing:0.12px;word-spacing:0.06px;}
#tw_171{left:35px;bottom:420px;word-spacing:0.19px;}
#tx_171{left:35px;bottom:397px;letter-spacing:-0.01px;word-spacing:0.2px;}
#ty_171{left:35px;bottom:374px;letter-spacing:0.21px;}
#tz_171{left:125px;bottom:381px;letter-spacing:-0.07px;}
#t10_171{left:183px;bottom:374px;letter-spacing:0.02px;word-spacing:-1.07px;}
#t11_171{left:35px;bottom:350px;letter-spacing:0.12px;word-spacing:0.06px;}
#t12_171{left:35px;bottom:327px;letter-spacing:0.11px;word-spacing:0.07px;}
#t13_171{left:35px;bottom:304px;letter-spacing:0.03px;word-spacing:0.16px;}
#t14_171{left:35px;bottom:281px;letter-spacing:0.13px;word-spacing:0.06px;}
#t15_171{left:35px;bottom:258px;letter-spacing:0.07px;word-spacing:0.11px;}
#t16_171{left:35px;bottom:234px;letter-spacing:0.01px;word-spacing:-0.51px;}
#t17_171{left:35px;bottom:211px;letter-spacing:0.09px;word-spacing:0.1px;}
#t18_171{left:35px;bottom:188px;letter-spacing:0.06px;word-spacing:0.13px;}
#t19_171{left:457px;bottom:195px;letter-spacing:-0.01px;}
#t1a_171{left:480px;bottom:188px;letter-spacing:-0.01px;word-spacing:0.19px;}
#t1b_171{left:35px;bottom:165px;letter-spacing:0.02px;word-spacing:-0.93px;}
#t1c_171{left:35px;bottom:141px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1d_171{left:35px;bottom:118px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t1e_171{left:515px;bottom:126px;letter-spacing:0.1px;}
#t1f_171{left:35px;bottom:95px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1g_171{left:618px;bottom:777px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1h_171{left:618px;bottom:754px;letter-spacing:0.02px;word-spacing:0.16px;}
#t1i_171{left:618px;bottom:713px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1j_171{left:618px;bottom:690px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1k_171{left:618px;bottom:667px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1l_171{left:618px;bottom:645px;letter-spacing:0.07px;word-spacing:0.13px;}
#t1m_171{left:847px;bottom:653px;letter-spacing:0.12px;}
#t1n_171{left:886px;bottom:645px;letter-spacing:0.3px;word-spacing:-0.11px;}
#t1o_171{left:618px;bottom:622px;letter-spacing:0.16px;word-spacing:0.12px;}
#t1p_171{left:618px;bottom:599px;letter-spacing:0.11px;word-spacing:0.07px;}
#t1q_171{left:618px;bottom:575px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t1r_171{left:618px;bottom:552px;letter-spacing:0.05px;word-spacing:0.31px;}
#t1s_171{left:618px;bottom:529px;letter-spacing:0.19px;}
#t1t_171{left:699px;bottom:536px;letter-spacing:0.15px;}
#t1u_171{left:798px;bottom:529px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1v_171{left:618px;bottom:506px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1w_171{left:618px;bottom:482px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1x_171{left:618px;bottom:459px;letter-spacing:0.1px;word-spacing:0.08px;}
#t1y_171{left:618px;bottom:436px;letter-spacing:0.06px;}
#t1z_171{left:658px;bottom:444px;letter-spacing:0.15px;}
#t20_171{left:689px;bottom:436px;letter-spacing:0.04px;word-spacing:-1.09px;}
#t21_171{left:618px;bottom:413px;letter-spacing:0.07px;word-spacing:-0.41px;}
#t22_171{left:618px;bottom:390px;letter-spacing:0.08px;word-spacing:-0.51px;}
#t23_171{left:618px;bottom:366px;letter-spacing:0.14px;word-spacing:0.04px;}
#t24_171{left:618px;bottom:343px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t25_171{left:618px;bottom:320px;letter-spacing:0.18px;word-spacing:0.01px;}
#t26_171{left:618px;bottom:297px;letter-spacing:0.08px;word-spacing:0.11px;}
#t27_171{left:852px;bottom:304px;letter-spacing:-0.01px;}
#t28_171{left:875px;bottom:297px;letter-spacing:0.05px;word-spacing:0.14px;}
#t29_171{left:618px;bottom:273px;letter-spacing:0.08px;word-spacing:-1.02px;}
#t2a_171{left:618px;bottom:250px;letter-spacing:0.08px;}
#t2b_171{left:618px;bottom:212px;}
#t2c_171{left:618px;bottom:188px;letter-spacing:0.18px;word-spacing:0.01px;}
#t2d_171{left:764px;bottom:188px;letter-spacing:0.25px;word-spacing:-0.06px;}
#t2e_171{left:946px;bottom:188px;letter-spacing:0.19px;}
#t2f_171{left:618px;bottom:165px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2g_171{left:1145px;bottom:172px;letter-spacing:0.61px;}
#t2h_171{left:618px;bottom:141px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2i_171{left:618px;bottom:118px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2j_171{left:1093px;bottom:126px;letter-spacing:-0.01px;}
#t2k_171{left:1116px;bottom:118px;letter-spacing:0.24px;word-spacing:-0.06px;}
#t2l_171{left:618px;bottom:95px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2m_171{left:618px;bottom:72px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2n_171{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_171{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_171{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_171{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_171{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_171{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_171{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_171{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_171{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s8_171{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts171" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg171Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg171" style="-webkit-user-select: none;"><object width="1210" height="935" data="171/171.svg" type="image/svg+xml" id="pdf171" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_171" class="t s0_171">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_171" class="t s1_171">© </span>
<span id="t3_171" class="t s0_171">(NCCN </span>
<span id="t4_171" class="t s1_171">© </span>
<span id="t5_171" class="t s0_171">), All rights reserved. NCCN Guidelines </span>
<span id="t6_171" class="t s1_171">® </span>
<span id="t7_171" class="t s0_171">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_171" class="t s2_171">NCCN Guidelines Version 4.2024 </span>
<span id="t9_171" class="t s2_171">Head and Neck Cancers </span>
<span id="ta_171" class="t s3_171">MS-30 </span>
<span id="tb_171" class="t s4_171">examination including tongue base palpation, or those who require </span>
<span id="tc_171" class="t s4_171">systemic therapy/RT and will not have their treatment plan affected, </span>
<span id="td_171" class="t s4_171">regardless of surgical evaluation. These situations remain the minority of </span>
<span id="te_171" class="t s4_171">cases. </span>
<span id="tf_171" class="t s4_171">Tumor HPV testing by use of surrogate p16 immunohistochemistry (IHC) </span>
<span id="tg_171" class="t s4_171">is now required for cancers of the oropharynx because of the new AJCC </span>
<span id="th_171" class="t s4_171">8 </span>
<span id="ti_171" class="t s5_171">th </span>
<span id="tj_171" class="t s4_171">edition staging system </span>
<span id="tk_171" class="t s5_171">391 </span>
<span id="tl_171" class="t s4_171">(see the following section on </span><span id="tm_171" class="t s6_171">HPV Testing</span><span id="tn_171" class="t s4_171">). </span>
<span id="to_171" class="t s7_171">HPV Testing </span>
<span id="tp_171" class="t s4_171">p16 expression correlates with HPV status in geographic regions where </span>
<span id="tq_171" class="t s4_171">HPV is etiologically responsible for a high proportion of cancers. </span>
<span id="tr_171" class="t s5_171">415,416 </span>
<span id="ts_171" class="t s4_171">There are currently no diagnostic tests with regulatory approval. The </span>
<span id="tt_171" class="t s4_171">NCCN Guidelines for Head and Neck Cancers recommend evaluation of </span>
<span id="tu_171" class="t s4_171">tumor HPV status by use of a surrogate of p16 IHC in all patients </span>
<span id="tv_171" class="t s4_171">diagnosed with an oropharyngeal cancer. Expression of p16 as detected </span>
<span id="tw_171" class="t s4_171">by IHC is a widely available surrogate biomarker that has very good </span>
<span id="tx_171" class="t s4_171">agreement with HPV status as determined by HPV E6/E7 mRNA </span>
<span id="ty_171" class="t s4_171">expression. </span>
<span id="tz_171" class="t s5_171">42,415-418 </span>
<span id="t10_171" class="t s4_171">Confirmatory HPV testing of tumor is recommended for </span>
<span id="t11_171" class="t s4_171">clinical trials of HPV-targeted therapeutics or designed to test de- </span>
<span id="t12_171" class="t s4_171">intensification strategies. Direct HPV confirmatory tests include </span>
<span id="t13_171" class="t s4_171">polymerase chain reaction (PCR) and RNA or DNA in situ hybridization </span>
<span id="t14_171" class="t s4_171">(ISH). The performance of various plasma cell-free HPV DNA detection </span>
<span id="t15_171" class="t s4_171">assays (preferably validated per CLIA and CAP regulatory guidelines) for </span>
<span id="t16_171" class="t s4_171">a diagnosis of HPV-positive oropharyngeal cancer against a gold standard </span>
<span id="t17_171" class="t s4_171">of E6/E7 mRNA detection is unknown. Sensitivity and specificity against </span>
<span id="t18_171" class="t s4_171">p16-IHC are approximately 90% and 94%, respectively. </span>
<span id="t19_171" class="t s5_171">419 </span>
<span id="t1a_171" class="t s4_171">At this time, </span>
<span id="t1b_171" class="t s4_171">persistent cell-free oncogenic HPV DNA detection in plasma (among those </span>
<span id="t1c_171" class="t s4_171">positive and quantifiable at diagnosis) may identify patients at increased </span>
<span id="t1d_171" class="t s4_171">risk for progression after completion of curative intent therapy. </span>
<span id="t1e_171" class="t s5_171">420,421 </span>
<span id="t1f_171" class="t s4_171">However, without concurrent clinical, radiographic or pathological </span>
<span id="t1g_171" class="t s4_171">correlates represents an outcome without actionable therapeutic </span>
<span id="t1h_171" class="t s4_171">implications outside of clinical trials. </span>
<span id="t1i_171" class="t s4_171">Analyses of HPV testing methods have shown that sensitivity and </span>
<span id="t1j_171" class="t s4_171">specificity of p16 IHC range from 94% to 97% and 83% to 84%, </span>
<span id="t1k_171" class="t s4_171">respectively, with sensitivity and specificity of HPV16 ISH ranging from </span>
<span id="t1l_171" class="t s4_171">85% to 88% and 88% to 95%. </span>
<span id="t1m_171" class="t s5_171">42,418 </span>
<span id="t1n_171" class="t s4_171">The reduced specificity for p16 IHC </span>
<span id="t1o_171" class="t s4_171">may be due to the presence of p16-positive tumors that do not have </span>
<span id="t1p_171" class="t s4_171">evidence of HPV DNA, while the reduced sensitivity for HPV16 ISH may </span>
<span id="t1q_171" class="t s4_171">be due to the presence of other high-risk HPV types in the tumor. PCR </span>
<span id="t1r_171" class="t s4_171">may provide additional sensitivity while ISH provides increased </span>
<span id="t1s_171" class="t s4_171">specificity. </span>
<span id="t1t_171" class="t s5_171">9,415,418,422,423 </span>
<span id="t1u_171" class="t s4_171">PCR may also increase false positive rates from </span>
<span id="t1v_171" class="t s4_171">specimen contamination; for example, by a prevalent oral oncogenic </span>
<span id="t1w_171" class="t s4_171">infection unrelated to the cancer in approximately 13% of U.S. men who </span>
<span id="t1x_171" class="t s4_171">smoke. Sufficient pathologic material for HPV testing can be obtained by </span>
<span id="t1y_171" class="t s4_171">FNA. </span>
<span id="t1z_171" class="t s5_171">9,424 </span>
<span id="t20_171" class="t s4_171">Institutions should evaluate concordance between p16 and direct </span>
<span id="t21_171" class="t s4_171">HPV testing, as this may vary by regions, particularly if considering use of </span>
<span id="t22_171" class="t s4_171">p16 IHC alone as a surrogate. According to the guidelines for HPV testing </span>
<span id="t23_171" class="t s4_171">published by the College of American Pathologists, when using p16, the </span>
<span id="t24_171" class="t s4_171">70% cutoff with nuclear and cytoplasmic expression with at least moderate </span>
<span id="t25_171" class="t s4_171">to strong intensity if recommended; see these guidelines for additional </span>
<span id="t26_171" class="t s4_171">information about HPV testing. </span>
<span id="t27_171" class="t s5_171">425 </span>
<span id="t28_171" class="t s4_171">HPV testing may prompt questions </span>
<span id="t29_171" class="t s4_171">about prognosis and sexual history that the clinician should be prepared to </span>
<span id="t2a_171" class="t s4_171">address. </span>
<span id="t2b_171" class="t s7_171">Staging </span>
<span id="t2c_171" class="t s4_171">The algorithms for </span><span id="t2d_171" class="t s6_171">Oropharyngeal Cancer </span><span id="t2e_171" class="t s4_171">in the NCCN Guidelines for </span>
<span id="t2f_171" class="t s4_171">Head and Neck Cancers reflect the staging criteria published in the 8 </span>
<span id="t2g_171" class="t s5_171">th </span>
<span id="t2h_171" class="t s4_171">edition of the AJCC Cancer Staging Manual for p16-negative </span>
<span id="t2i_171" class="t s4_171">oropharyngeal cancer and p16-positive oropharyngeal cancer. </span>
<span id="t2j_171" class="t s5_171">391 </span>
<span id="t2k_171" class="t s4_171">In the </span>
<span id="t2l_171" class="t s4_171">staging criteria for p16-negative oropharyngeal cancer, separate </span>
<span id="t2m_171" class="t s4_171">pathologic criteria are now presented for involvement of regional lymph </span>
<span id="t2n_171" class="t s8_171">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
